Lucis secured a $20m Series A raise to move full steam ahead on accelerating the growth of the preventative health platform, which uses data to drive a paradigm shift in healthcare from disease treatment in later stages to early detection and prevention.
The oversubscribed round saw a strong syndicate led by leading European early-stage venture capital fund Singular and included institutional investors such as General Catalyst and Y Combinator, as well as a list of well-known angels, including Céline Lazorthes and Manu Lecomte.
What is additionally impressive is the fact that this Series A closes only four months after the company closed an $8.5 million seed round in late 2025. This extension of the recently formed startup’s capitalisation to around $28 million in its first year of business demonstrates significant investor appetite for ventures combining cutting-edge A.I. and clinical safety practices.
Turning Complex Lab Data Into Actionable Intelligence
Founded in 2025 by tech entrepreneurs Maxime Berthelot and Baptiste Debever, Lucis graduated from Y Combinator’s 2025 batch with a clear mission: making preventive health the default approach rather than an exclusive privilege.
‘The platform seeks to address existing fragmentation in diagnostic testing. By interfacing with Europe’s largest laboratory networks, such as Eurofins and Randox, Lucis members are able to access standard blood samples from over 450 accredited facilities.
Yet while standard examinations for medical health only test for a small handful of standard parameters, Lucis measures more than 110 different indicators across eleven vital body systems: metabolism, cardiovascular, hormones, inflammation, nutrition, etc.
Source: Lucis
This lab data, with a very high level of granularity, is directly uploaded to the Lucis AI companion app. Instead of providing an irrelevant static PDF lab report, which leads to patient confusion, the proprietary AI model interprets the several biomarker readings in conjunction with the continuous metrics of the wearable tracker, the patient’s lifestyle history, and longitudinal medical records.
These are converted into daily personalised action plans to optimise nutrition, supplementation, sleep and workouts. A dedicated network of physicians reviews the recommendations with strict regard for medical accuracy before they are presented to the user.
More News: Modal Raises $355M as AI Infrastructure Demand Surges
Demonstrating Clear Clinical Outcomes
Lucis is entering the market at a critical macroeconomic juncture. According to World Health Organization reports, chronic non-communicable illnesses like type 2 diabetes and heart disease cause 1.8 million avoidable deaths annually across Europe. Lucis argues that up to 80% of these cases are fundamentally preventable if risk factors are caught and managed early.
The startup’s early commercial metrics suggest that its proactive model is working. Since its launch, Lucis has grown its active user base to over 10,000 members across France, the United Kingdom, Ireland, and Portugal, running more than one million cumulative biomarker analyses.
More importantly, the company’s internal data showcase genuine behavioural changes and clinical results. At baseline testing, an astonishing 99.9% of users had at least one biomarker falling outside the optimal physiological range, often without any prior awareness or physical symptoms.
Following continuous adherence to the platform’s AI protocols, 75% of users who completed a six-month follow-up successfully improved at least three of their deficient health biomarkers completely organically, without the introduction of prescription medications. Furthermore, the platform boasts a customer retention signal, with more than 80% of members proactively opting to complete secondary follow-up testing cycles.
Mapping the Pan-European Footprint
“We’ve seen the devastating impact of late-stage diagnosis firsthand,” said Maxime Berthelot, co-founder and CEO of Lucis, in a statement that accompanied the announcement. “What’s lacking is a system that can take action before symptoms manifest; the science is already there. We can identify what the conventional reactive system overlooks by merging biomarker data with AI-driven clinical insights.”
The newly acquired $20 million will be used to scale the company’s workforce and deepen its engineering investments into long-term longitudinal health tracking and clinical safety algorithms.
Additionally, the funding will fuel an aggressive international go-to-market push. Currently dominant in Western Europe, Lucis plans to establish physical laboratory partnerships and launch its digital application in Spain, Germany, and Italy by the end of 2026, positioning itself to capture the lion’s share of the booming European preventive digital health sector.
Source link
